Archive for 2014

Drug Patent Expirations for April 1 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

FDA Orange Book archives from 2005 to present

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for April 1 2014

Tradename Applicant Generic Name Patent
Expiration
ABELCET

Sigma Tau

amphotericin b

Apr 1, 2014
FROVA

Endo Pharms

frovatriptan succinate

Apr 1, 2014
MAXALT-MLT

Merck

rizatriptan benzoate

Apr 1, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Bioterrorism and bioethics: Challenges for industry, government and society

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Bioterrorism and bioethics: Challenges for industry, government and society
Go to paperABSTRACT: The emerging threat of bioterrorism raises important chall…


Why do so many scientists fail as entrepreneurs?

This is a guest post by Gerry Langeler, Managing Director with OVP Venture Partners. Do you have a response to Gerry’s post? Respond in the comments section below. Many scientists conduct research they believe can have commercial value, and so they fancy themselves as budding entrepreneurs. But a remarkable number stumble over predictable hurdles when they […]


Drug Patent Expirations for March 30 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

FDA Orange Book archives from 2005 to present

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for March 30 2014

Tradename Applicant Generic Name Patent
Expiration
BUSULFEX

Otsuka Pharm

busulfan

Mar 30, 2014
LIDODERM

Teikoku Pharma Usa

lidocaine

Mar 30, 2014
RAPAMUNE

Pf Prism Cv

sirolimus

Mar 30, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Drug Patent Expirations for March 24 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for March 24 2014

Tradename Applicant Generic Name Patent
Expiration
ZORTRESS

Novartis

everolimus

Mar 24, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Is the future of Google Glass in the life sciences?

I have been struggling to understand the utility of Google Glass in most of the presented use cases. The Google Glass homepage features largely recreational consumer-driven uses, such as taping a ballet concert, performing Google searches, and navigation. A regular cellphone or GoPro can readily serve these needs, which leads me to question where the killer […]


ATMP in practice: Towards a new industry landscape in tissue engineering

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
ATMP in practice: Towards a new industry landscape in tissue engineering
Go to paperABSTRACT: Regulatory divergences and market fragmentation across member…


Drug Patent Expirations for March 21 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

BiologicPatentWatch -- biologic drug patent expiration information

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for March 21 2014

Tradename Applicant Generic Name Patent
Expiration
LIPTRUZET

Merck Sharp Dohme

atorvastatin calcium; ezetimibe

Mar 21, 2014
MONISTAT 1 COMBINATION PACK

Insight Pharms

miconazole nitrate

Mar 21, 2014
VYTORIN

Msd Intl

ezetimibe; simvastatin

Mar 21, 2014
ZETIA

Msd Intl Gmbh

ezetimibe

Mar 21, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


New issue of the Journal of Commercial Biotechnology

The April 1 2014 issue of the Journal of Commercial Biotechnology has just been published, and features the following papers: Building biotechnology in India – Drugs are not the answer Yali Friedman I have had the pleasure of participating in national forums on biotechnology development in diverse countries. A common theme I see is that […]